This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Pulmonary Diseases  • Asthma  • Drug Therapy  • Adverse Effects  • Immunology  • Allergy  • Alert me on articles by topic  Social Bookmarking   What's this?

Bridget M. Kuehn

JAMA. 2009;301(4):365-366.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

A panel of advisors to the US Food and Drug Administration (FDA) recommended that the agency ban the marketing of 2 popular asthma drugs that have been associated with an increased risk of rare but serious adverse events and, in some cases, death.

Asthma treatments containing long-acting β-agonists alone are associated with an increased risk of rare but serious adverse events. (Photo credit: Ted Grudzinski/AMA)

The panel was charged with assessing the risks and benefits of certain asthma treatments, specifically the long-acting β-agonist (LABA) drugs formoterol and salmeterol and combination products containing both a LABA and an inhaled corticosteroid (formoterol plus budesonide and salmeterol plus fluticasone). Previously, the FDA’s Office of Drug Safety and the agency’s pulmonary and allergy drug products division had made contradictory recommendations concerning LABAs.

The panel, which consisted of members from 3 committees that advise the FDA on drug safety, pediatric issues, and . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?